Cartesian Therapeutics

Filed a patent for "chimeric antigen receptors adapted for prolonged expression" on Fri, March 17, 2023

Filed a patent for "diffusion-limited, lymph-node-targeted particles for in vivo expression of chimeric antigen receptors" on Mon, March 20, 2023

Filed a patent for "multiprotein-engineered cells secreting a multispecific antibody" on Fri, January 26, 2024

Filed a patent for "engineered cells secreting therapeutic enzymes" on Thu, June 8, 2023